The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
- 
      
  
Rapid Response Innovation Awards, 2010In Vivo Assessment of Alpha-Synuclein SecretionObjective/Rationale: 
 Recent data from our lab (Emmanouilidou et al, 2010) suggest that cell-produced physiologically secreted alpha-synuclein can cause the death of neuronal recipient cells. Although...
- 
      
  
Therapeutics Development Initiative, 2010Selective Inhibition of Cyclic Nucleotide Phosphodiesterase Type 7 (PDE7): A Novel and Efficacious Approach to Treating Parkinson's DiseasePromising Outcomes of Original Grant: 
 We are investigating a regulatory enzyme (type-7 cyclic nucleotide phosphodiesterase, PDE7) as a novel therapeutic target for the treatment of Parkinson’s disease...
- 
      
  
MJFF Research Grant, 2010Regulated rAAV-GDNF to treat Parkinson's disease: Translational research planObjective/Rationale: 
 We are attempting to perfect gene therapy using glial cell line-derived neurotrophic factor (GDNF) for Parkinson’s disease. One part of developing this gene therapy is...
- 
      
  
Neurotrophic Factor Therapies for Parkinson's Disease, 2010CDNF (Cerebral Dopamine Neurotrophic Factor) for Therapy of Parkinson's DiseaseObjective/Rationale: 
 CDNF protein is expressed in human brain, acts differently from known neurotrophic factors and can protect and repair dopamine neurons in two pre-clinical models of Parkinson’s...
- 
      
  
Target Validation, 2009Testing PDE-1 Inhibitor in MPTP-treated MacaquesPromising Outcomes of Original Grant: 
 Our goal is to develop novel therapeutic molecules that promote normal dopamine neurotransmission in the brain affected by PD. We hypothesize that these molecules...
- 
      
  
Rapid Response Innovation Awards, 2010Selective Neuroprotective Effects of the S18Y Polymorphic Variant of UCH-L1Promising Outcomes of Original Grant: 
 We were able to replicate in an in vivo setting in the nigrostriatal system our previous observation in neuronal cell cultures that lack of UCH-L1 did not alter...
 
  Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.